Long-term remission induced by low-dose rituximab for relapsed and refractory thrombotic thrombocytopenic purpura: A report of two cases

Experimental and Therapeutic Medicine

Volumn 10, Issue 6, 2015, Pages 2295-2298

  Tong, Hong Yan ^a,b   Ye, Li ^a,b   Ye, Xing Nong ^a,b   Lu, De Min ^a,b   Li, Ying ^a,b  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

ADAMTS13; Low dose; Rituximab; Thrombotic thrombocytopenic purpura

Indexed keywords

BILIRUBIN; CYCLOSPORIN A; DEXAMETHASONE; HEMOGLOBIN; IMMUNOSUPPRESSIVE AGENT; LACTATE DEHYDROGENASE; METHYLPREDNISOLONE; PREDNISONE; RITUXIMAB; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECCHYMOSIS; ECHOGRAPHY; ERYTHROCYTE COUNT; FEMALE; FOLLOW UP; HEMATURIA; HUMAN; HYPERPLASIA; LOW DRUG DOSE; MALE; NAUSEA AND VOMITING; PETECHIA; PLASMA TRANSFUSION; PLASMAPHERESIS; REMISSION; RETICULOCYTE COUNT; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 84946542619     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2015.2797     Document Type: Article

References (16)

1. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC and Spasoff RA: Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 325: 393‑397, 1991.
2. Tsai HM: Current concepts in thrombotic thrombocytopenic purpura. Annu Rev Med 57: 419‑436, 2006.
3. Allford SL, Hunt BJ, Rose P and Machin SJ; Haemostasis and Thrombosis Task Force, British Committee for Standards in Haemotology: Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol 120: 556‑573, 2003.
4. Zaja F, Baccarani M, Mazza P, Bocchia M, Gugliotta L, Zaccaria A, Vianelli N, Defina M, Tieghi A, Amadori S, et al: Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood 115: 2755‑2762, 2010.
5. Patel VL, Mahévas M, Lee SY, Stasi R, Cunningham-Rundles S, Godeau B, Kanter J, Neufeld E, Taube T, Ramenghi U, et al: Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood 119: 5989‑5995, 2012.
6. Zaja F, Vianelli N, Volpetti S, Battista ML, Defina M, Palmieri S, Bocchia M, Medeot M, De Luca S, Ferrara F, et al: Low‑doserituximab in adult patients with primary immune thrombocy- topenia. Eur J Haematol 85: 329‑334, 2010.
7. Zecca M, De Stephano P, Nobili B and Locatelli F: Anti‑CD20 monoclonal antibody for the treatment of severe, immune‑mediated, pure red cell aplasia and hemolytic anaemia. Blood 97: 3995-3997, 2001.
8. Fakhouri F, Vernant JP, Veyradier A, Wolf M, Kaplanski G, Binaut R, Rieger M, Scheiflinger F, Poullin P, Deroure B, et al: Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13‑deficient thrombotic thrombocytopenic purpura: A study of 11 cases. Blood 106: 1932‑1937, 2005.
9. Scully M, McDonald V, Cavenagh J, Hunt BJ, Longair I, Cohen H and Machin SJ: A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood 118: 1746‑1753, 2011.
10. Froissart A, Buffet M, Veyradier A, Poullin P, Provôt F, Malot S, Schwarzinger M, Galicier L, Vanhille P, Vernant JP, et al: Efficacy and safety of first‑line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French thrombotic microangi- opathies reference center. Crit Care Med 40: 104‑111, 2012.
11. Iioka F, Shimomura D, Ishii T, Maesako Y, Ohgoe K, Nakamura F, Matsuo S and Ohno H: Short‑ and long‑term effects of rituximab for the treatment of thrombotic thrombocytopenic purpura: Four case reports. Int J Hematol 96: 506‑512, 2012.
12. de la Rubia JD, Moscardó F, Gómez MJ, Guardia R, Rodríguez P, Sebrango A, Zamora C, Debén G, Goterris R, López R, et al: Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: Results of a Spanish multicenter study. Transfus Apher Sci 43: 299‑303, 2010.
13. Scully M, Hunt BJ, Benjamin S, Liesner R, Rose P, Peyvandi F, Cheung B and Machin SJ; British Committee for Standards in Haematology: Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 158: 323‑335, 2012.
14. Pequeño-Luévano M, Villarreal-Martínez L, Jaime-Pérez JC, Gómez-de-León A, Cantú-Rodríguez OG, González-Llano O and Gómez-Almaguer D: Low‑dose rituximab for the treatment of acute thrombotic thrombocytopenic purpura: Report of four cases. Hematology 18: 233‑236, 2013.
15. Taube T, Schmid H, Reinhard H, von Stackelberg A and Overberg US: Effect of a single dose of rituximab in chronic immune thrombocytopenic purpura in childhood. Haematologica 90: 281‑283, 2005.
16. Zaja F, Battista ML, Pirrotta MT, Palmieri S, Montagna M, Vianelli N, Marin L, Cavallin M, Bocchia M, Defina M, et al: Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura. Haematologica 93: 930‑933, 2008